432 related articles for article (PubMed ID: 16899320)
1. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
[TBL] [Abstract][Full Text] [Related]
2. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
Etrych T; Jelínková M; Ríhová B; Ulbrich K
J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
[TBL] [Abstract][Full Text] [Related]
3. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
4. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
5. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
6. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
7. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
[TBL] [Abstract][Full Text] [Related]
8. HPMA-based polymer conjugates with drug combination.
Krakovicová H; Etrych T; Ulbrich K
Eur J Pharm Sci; 2009 Jun; 37(3-4):405-12. PubMed ID: 19491032
[TBL] [Abstract][Full Text] [Related]
9. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
[TBL] [Abstract][Full Text] [Related]
11. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
12. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors.
Etrych T; Strohalm J; Chytil P; Říhová B; Ulbrich K
J Drug Target; 2011 Dec; 19(10):874-89. PubMed ID: 21978286
[TBL] [Abstract][Full Text] [Related]
13. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
14. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization.
Chytil P; Šírová M; Koziolová E; Ulbrich K; Říhová B; Etrych T
Physiol Res; 2015; 64(Suppl 1):S41-9. PubMed ID: 26447594
[TBL] [Abstract][Full Text] [Related]
15. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.
Etrych T; Sírová M; Starovoytova L; Ríhová B; Ulbrich K
Mol Pharm; 2010 Aug; 7(4):1015-26. PubMed ID: 20518512
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting.
Etrych T; Strohalm J; Chytil P; Černoch P; Starovoytova L; Pechar M; Ulbrich K
Eur J Pharm Sci; 2011 Apr; 42(5):527-39. PubMed ID: 21392579
[TBL] [Abstract][Full Text] [Related]
17. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
[TBL] [Abstract][Full Text] [Related]
18. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
20. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]